Yet how will our system contemplate funding high-cost therapies that deliver potentially curative benefits over such a wide range of years - from 5 to 75 years. …
New CAR-T data once again highlights the evaluation challenge
June 5, 2019 Latest NewsNews of the Day
Latest Video
New Stories
-
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News -
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech